Malignant Solid Tumour Clinical Trial
Official title:
Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous schedule at differing dose levels. The primary objective of this study is to determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors.
This is an open-label, phase I study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion on a standard dose and schedule (weekly, with the first dose at 400 mg/m2 and all subsequent weekly doses at 250 mg/m2). Dasatinib will be administered orally on a continuous schedule at the following dose levels: 100 mg QD (once a day), 150 mg QD, and 200 mg QD. Three to six patients will be enrolled at each dose level, and the final recommended phase II cohort will be expanded to include up to 12 additional patients. The doses will be escalated in successive cohorts of patients. On cycle 1, dasatinib administration will start one day prior to cetuximab administration. One cycle will be defined as 21 days, and cycles will continue until progression of disease or intolerable toxicities occur. Peripheral blood samples and pharmacokinetic blood samples will be taken on days 0, 1, 15, and 16 of Cycle 1 only. In patients with accessible tumor that give consent, patients will undergo a baseline tumor biopsy and a repeat biopsy after 14-21 days of the first cycle. ;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01721148 -
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
|
Phase 1 | |
| Completed |
NCT00551096 -
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01023737 -
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01435096 -
BN80927 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT01951846 -
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
|
Phase 1 | |
| Completed |
NCT01325558 -
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01554371 -
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01286896 -
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT01309490 -
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT01376505 -
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01611857 -
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
|
Phase 1/Phase 2 | |
| Completed |
NCT02843204 -
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02853903 -
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
|
Phase 2 | |
| Completed |
NCT01618136 -
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT00801151 -
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02786628 -
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT01184807 -
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00969410 -
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
|
Phase 1 | |
| Completed |
NCT02857920 -
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
|
Phase 1/Phase 2 |